Siga Technologies Inc (SIGA)

$6.96

+0.04

(+0.58%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $6.80
    $7.01
    $6.96
    downward going graph

    2.3%

    Downside

    Day's Volatility :3.0%

    Upside

    0.71%

    downward going graph
  • $4.26
    $12.83
    $6.96
    downward going graph

    38.79%

    Downside

    52 Weeks Volatility :66.8%

    Upside

    45.75%

    downward going graph

Returns

PeriodSiga Technologies IncSector (Health Care)Index (Russel 2000)
3 Months
-12.79%
7.5%
0.0%
6 Months
-31.89%
6.9%
0.0%
1 Year
29.31%
20.9%
0.0%
3 Years
-9.88%
21.0%
-21.1%

Highlights

Market Capitalization
481.7M
Book Value
$2.35
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.17
PE Ratio
5.77
PEG Ratio
0.0
Wall Street Target Price
17.53
Profit Margin
48.55%
Operating Margin TTM
4.95%
Return On Assets TTM
37.86%
Return On Equity TTM
57.59%
Revenue TTM
173.0M
Revenue Per Share TTM
2.43
Quarterly Revenue Growth YOY
271.0%
Gross Profit TTM
77.8M
EBITDA
103.3M
Diluted Eps TTM
1.17
Quarterly Earnings Growth YOY
2.72
EPS Estimate Current Year
1.01
EPS Estimate Next Year
1.25
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 151.87%

Current $6.96
Target $17.53

Company Financials

FY18Y/Y Change
Revenue
477.1M
↑ 3788.3%
Net Income
421.8M
↓ 1264.07%
Net Profit Margin
88.42%
↑ 383.76%
FY19Y/Y Change
Revenue
26.7M
↓ 94.39%
Net Income
-7.2M
↓ 101.72%
Net Profit Margin
-27.08%
↓ 115.5%
FY20Y/Y Change
Revenue
125.0M
↑ 367.28%
Net Income
56.3M
↓ 878.08%
Net Profit Margin
45.09%
↑ 72.17%
FY21Y/Y Change
Revenue
133.7M
↑ 6.97%
Net Income
69.5M
↑ 23.27%
Net Profit Margin
51.96%
↑ 6.87%
FY22Y/Y Change
Revenue
110.8M
↓ 17.13%
Net Income
33.9M
↓ 51.18%
Net Profit Margin
30.61%
↓ 21.35%
FY23Y/Y Change
Revenue
139.9M
↑ 26.31%
Net Income
68.1M
↑ 100.76%
Net Profit Margin
48.65%
↑ 18.04%
Q1 FY23Q/Q Change
Revenue
8.3M
↓ 26.72%
Net Income
-918.3K
↑ 13.11%
Net Profit Margin
-11.03%
↓ 3.88%
Q2 FY23Q/Q Change
Revenue
5.9M
↓ 29.37%
Net Income
-2.9M
↑ 213.15%
Net Profit Margin
-48.92%
↓ 37.89%
Q3 FY23Q/Q Change
Revenue
9.2M
↑ 57.11%
Net Income
-393.1K
↓ 86.33%
Net Profit Margin
-4.26%
↑ 44.66%
Q4 FY23Q/Q Change
Revenue
116.5M
↑ 1161.27%
Net Income
72.3M
↓ 18482.57%
Net Profit Margin
62.03%
↑ 66.29%
Q1 FY24Q/Q Change
Revenue
25.4M
↓ 78.17%
Net Income
10.3M
↓ 85.78%
Net Profit Margin
40.41%
↓ 21.62%
Q2 FY24Q/Q Change
Revenue
21.8M
↓ 14.23%
Net Income
1.8M
↓ 82.17%
Net Profit Margin
8.4%
↓ 32.01%
FY18Y/Y Change
Total Assets
203.4M
↑ 40.63%
Total Liabilities
100.5M
↓ 78.51%
FY19Y/Y Change
Total Assets
198.6M
↓ 2.4%
Total Liabilities
100.8M
↑ 0.25%
FY20Y/Y Change
Total Assets
149.8M
↓ 24.54%
Total Liabilities
20.0M
↓ 80.12%
FY21Y/Y Change
Total Assets
214.7M
↑ 43.31%
Total Liabilities
40.4M
↑ 101.68%
FY22Y/Y Change
Total Assets
195.0M
↓ 9.17%
Total Liabilities
24.9M
↓ 38.44%
FY23Y/Y Change
Total Assets
254.8M
↑ 30.66%
Total Liabilities
58.0M
↑ 133.07%
Q1 FY23Q/Q Change
Total Assets
183.9M
↓ 5.7%
Total Liabilities
21.8M
↓ 12.24%
Q2 FY23Q/Q Change
Total Assets
146.5M
↓ 20.34%
Total Liabilities
22.4M
↑ 2.78%
Q3 FY23Q/Q Change
Total Assets
158.4M
↑ 8.1%
Total Liabilities
34.2M
↑ 52.61%
Q4 FY23Q/Q Change
Total Assets
254.8M
↑ 60.9%
Total Liabilities
58.0M
↑ 69.33%
Q1 FY24Q/Q Change
Total Assets
243.1M
↓ 4.59%
Total Liabilities
78.2M
↑ 34.8%
Q2 FY24Q/Q Change
Total Assets
192.7M
↓ 20.76%
Total Liabilities
25.1M
↓ 67.88%
FY18Y/Y Change
Operating Cash Flow
68.9M
↓ 944.19%
Investing Cash Flow
78.2M
↓ 78239.67%
Financing Cash Flow
-3.8M
↑ 551.09%
FY19Y/Y Change
Operating Cash Flow
-18.2M
↓ 126.43%
Investing Cash Flow
-29.1K
↓ 100.04%
Financing Cash Flow
-1.2M
↓ 69.14%
FY20Y/Y Change
Operating Cash Flow
71.5M
↓ 492.87%
Investing Cash Flow
-15.5K
↓ 46.72%
Financing Cash Flow
-114.6M
↑ 9640.14%
FY21Y/Y Change
Operating Cash Flow
11.5M
↓ 83.93%
Investing Cash Flow
-50.6K
↑ 226.56%
Financing Cash Flow
-26.2M
↓ 77.14%
Q1 FY23Q/Q Change
Operating Cash Flow
24.4M
↓ 401.58%
Investing Cash Flow
-21.7K
↑ 0.0%
Financing Cash Flow
-7.6M
↑ 164.91%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.6M
↓ 114.64%
Investing Cash Flow
-21.7K
↑ 0.0%
Financing Cash Flow
-35.9M
↑ 374.59%

Technicals Summary

Sell

Neutral

Buy

Siga Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Siga Technologies Inc
Siga Technologies Inc
-12.56%
-31.89%
29.31%
-9.88%
31.84%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-7.9%
-16.26%
4.26%
14.31%
28.12%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
4.13%
28.4%
27.47%
42.78%
42.78%
Zoetis Inc.
Zoetis Inc.
6.43%
19.89%
14.71%
0.87%
57.21%
Viatris Inc.
Viatris Inc.
-2.35%
-3.41%
20.31%
-13.55%
-28.95%
Catalent, Inc.
Catalent, Inc.
-0.21%
6.86%
37.82%
-53.05%
26.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Siga Technologies Inc
Siga Technologies Inc
5.77
5.77
0.0
1.01
0.58
0.38
0.0
2.35
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
34.6
34.6
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
34.42
34.42
1.51
0.4
0.07
0.04
0.01
1.82
Zoetis Inc.
Zoetis Inc.
38.14
38.14
2.65
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.86
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Siga Technologies Inc
Siga Technologies Inc
NA
$481.7M
31.84%
5.77
48.55%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.6B
28.12%
34.6
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$48.6B
42.78%
34.42
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$88.3B
57.21%
38.14
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-28.95%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$10.9B
26.35%
211.02
-23.81%

Insights on Siga Technologies Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 116.48M → 21.81M (in $), with an average decrease of 46.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 72.25M → 1.83M (in $), with an average decrease of 84.0% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 37.8% return, outperforming this stock by 8.5%

Institutional Holdings

  • BlackRock Inc

    5.48%

  • First Wilshire Securities Mgmt Inc (CA)

    3.69%

  • Vanguard Group Inc

    3.42%

  • AltraVue Capital, LLC

    3.05%

  • Dimensional Fund Advisors, Inc.

    2.55%

  • Van Lanschot Kempen Investment Management NV

    2.41%

Company Information

at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.

Organization
Siga Technologies Inc
Employees
45
CEO
Mr. Daniel J. Luckshire
Industry
Health Technology

Discover More

FAQs